Severe complicated COVID-19

Severe complicated COVID-19 refers to the serious clinical presentation of illness caused by SARS-CoV-2, defined within surveillance frameworks to identify patients requiring prompt assessment and hospital-level care ^[1].

Severe presentations can include lower respiratory tract involvement, hypoxemia, and respiratory distress that necessitates hospitalization ^[1]. Common symptoms across the spectrum of SARS-CoV-2 infection include fever, cough, and constitutional complaints, with gastrointestinal symptoms sometimes preceding fever or lower respiratory signs; anosmia and ageusia have become less common since Omicron became predominant ^[1]. Ocular and dermatologic manifestations have also been documented, with some skin findings associated with increased severity ^[1]. Breakthrough and reinfection can occur even among individuals who are up to date with vaccination or have prior infection ^[1].

Within the severe-disease surveillance concept, older age, immunocompromise, and specific underlying medical conditions are the leading risk factors for progression to severe outcomes ^[1]. Population-level distribution of severe COVID-19 mirrors the prevalence of these predisposing factors, with the highest burden observed among older adults and medically vulnerable groups ^[1]. Incubation periods have shortened across successive waves, with pooled early-pandemic estimates near 6.5 days, approximately 4.3 days during Delta predominance, and 3–4 days during Omicron predominance ^[1]. The evidence does not provide direct disease-level occurrence or outbreak statistics for severe complicated COVID-19 beyond these risk-group descriptions.

SARS-CoV-2 can be transmitted by infected individuals regardless of vaccination status, and by those who are asymptomatic, pre-symptomatic, or symptomatic ^[1]. Peak transmissibility occurs from just before symptom onset through the first few days of illness, though most patients can continue shedding virus for up to approximately ten days following infection ^[1]. Spread occurs principally through respiratory particles, especially in close contact or poorly ventilated indoor settings ^[1].

Staying up to date with recommended COVID-19 vaccination and following CDC respiratory-virus guidance are the principal measures to reduce the risk of infection, hospitalization, and death from SARS-CoV-2 ^[1]. Clinicians are advised to encourage all patients to adhere to respiratory-virus guidance and to recommend that infected patients follow CDC recommendations for preventing spread while infectious ^[1]. These prevention measures apply across the spectrum of disease severity, with particular importance for populations at higher risk of severe outcomes ^[1].

1. 1US Centers for Disease Control and Prevention. Clinical Presentation | Covid | CDC [Internet]. cited 3 Sept 2026.Available from: https://www.cdc.gov/covid/hcp/clinical-care/covid19-presentation.html